Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05383001 |
| Title | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check) |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | AIO-Studien-gGmbH |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Asklepios Fachkliniken München-Gauting | Gauting | 82131 | Germany | Details |